Skip to main content
. Author manuscript; available in PMC: 2016 Jan 20.
Published in final edited form as: Cell Rep. 2015 Dec 10;13(11):2553–2564. doi: 10.1016/j.celrep.2015.11.043

Figure 6. IM-CKV063 provides superior protection against CHIKV compared to other tested NAbs.

Figure 6

Four week-old WT mice were treated with 100 µg of indicated mAbs four hours following subcutaneous inoculation with 103 FFU CHIKV-LR in the left rear footpad. WNV E60 and WNV hE16 served as mouse and human isotype control mAbs. (A) Viral load was determined in both ipsilateral and contralateral ankles at 3 days post infection. Statistical significance was determined by a Kruskal-Wallis test with a Dunn’s multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001) (n = 6 to 7). (B) Footpad size in the ipsilateral joint was measured prior to and 3 days following infection. Statistical significance was determined by ANOVA with a Dunnett’s multiple comparison test (**, P < 0.01; ***, P < 0.001)(n = 6 to 7).